Skip to main content

Table 1 A selection of published surveys concerning possible clinical benefits (transmission or progression) of the CCR5-delta32 heterozygous genotype

From: Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion

N=

Study population

Benefit tested

Significance

Reference

1427

HIV + vs. sero-negative control group

Transmission

P = 0.012

[8]

30

ESN

Transmission

P = 0.04

[9]

54

ESN

Transmission

P = 0.05*

[10]

2605

Woman

Transmission

OR: 0.63 (95% CI 0.44-0.90)

[11]

2996

High risk groups

Transmission

Risk = 0.30 (95% CI: 0.08-0.97)

[12]

1252

MSM

Transmission

NS

[13]

1200

HIV + vs control

Transmission, progression to AIDS

Both significant

[14]

108

IDU

Progression to AIDS

NS

[15]

127

Children

Progression to AIDS

Significant (p = 0.008) Effect is abrogated in case of a SDF1-3′A genotype

[16]

1955

Hemophilia patients

Progression to AIDS

Significant

[17]

512

Mother-child

Transmission, progression to AIDS

NS, significant

[18]

  1. These controversial data suggest that there might be additional factors beside the CCR5-delta32 genotype like SDF 1-3′ which contribute to the clinical outcome of transmission and infection. (ESN = exposed seronegative, MSM = men having sex with men, IDU = injecting drug users, CI = confidence interval, OR = odds ratio, NS = not significant) *only significant in heterosexuals.